CNBX Pharmaceuticals Faces Financial Struggles Amid Cuts and Hope for Clinical Trials

CNBX Pharmaceuticals Inc. (OTCBB: CNBX) Overview

CNBX Pharmaceuticals is a pre-clinical-stage biopharmaceutical company focused on developing innovative therapies, particularly for oncology and colorectal cancer. As of the latest report for the quarter ended May 31, 2025, CNBX continues to face operational challenges, with no reported revenues, leading to ongoing net losses.

Key Financial Metrics

• Cash Position: $13,648 as of May 31, 2025, down from $26,416 as of August 31, 2024.
• Revenues: $0 for both the three and nine months ended May 31, 2025, compared to $130,074 for the nine months ended May 31, 2024.
• Total Operating Expenses: $40,380 for Q3 2025, down from $152,278 in Q3 2024. Total for the nine months ended May 31, 2025 was $141,960, compared to $660,680 in the same period last year.
• Net Loss: $59,727 for the quarter ended May 31, 2025; $163,867 for the nine months; significantly reduced from a loss of $634,614 in the same nine months of 2024.
• Accumulated Deficit: $25,118,267 as of May 31, 2025.
• Stockholders' Equity: A deficit of $2,537,405, reflecting continuing financial challenges.
• Shares Outstanding: 92,511,352 shares as of May 31, 2025.

Positive Aspects

• Operational expenses have significantly decreased year-over-year, suggesting cost-cutting measures are being effectively implemented.
• The company is expected to start first-in-human Phase I/II clinical trials for its RCC-33 colorectal cancer therapy in 2025, potentially increasing future revenue streams.
• Recent exercise of a convertible loan to shares has provided some capital inflow.

Negative Aspects

• Lack of revenue continues to be a serious concern; the company has reported $0 revenues for the past quarter and year-to-date comparisons.
• Net losses continue to accumulate, indicating ongoing operational difficulties and financial strain.
• The accumulated deficit raises doubts about the company's ability to remain a going concern without significant revenue generation or additional funding.
• Cash reserves have decreased sharply, limiting liquidity for operational expenses in the near term.

This review highlights CNBX's pressing financial challenges alongside some strategic forward-looking plans in research and development. Investors should consider both the operational expenditures and the lack of generated revenue when evaluating the company's current and future standings.